PATHOPHYSIOLOGIC MECHANISMS LINKING ADIPOSE TISSUE AND CARDIOMETABOLIC RISK

被引:24
作者
Allende-Vigo, Myriam Zaydee [1 ]
机构
[1] Univ Puerto Rico Med Sci, Dept Med, Endocrine Sect, San Juan, PR USA
关键词
ADIPOSOPATHY SICK FAT; ENDOCANNABINOID SYSTEM; METABOLIC SYNDROME; ABDOMINAL OBESITY; BLOOD-PRESSURE; INSULIN; HYPERTENSION; ADIPONECTIN; DYSFUNCTION; MANAGEMENT;
D O I
10.4158/EP09340.RA
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe the contribution of adipocytes and adipose tissue to increased cardiometabolic risk as well as the mechanisms by which adipose tissue and obesity contribute to dysglycemia, dyslipidemia, hypertension, and a prothrombotic, inflammatory state favoring atherogenesis. Methods: A review was undertaken of the relevant available reports, compiled by means of a search (PubMed) of the English-language literature published between 1994 and 2010. Results: Coronary risk factors cause susceptibility to development of atherosclerosis. Traditional coronary risk factors are obesity, smoking, hypertension, diabetes, elevated serum cholesterol levels, male sex, advancing age, and a family history of early coronary events. The currently preferred term of cardiometabolic risk encompasses both the traditional coronary risk factors and the additional contributing factors of insulin resistance, atherogenic dyslipidemia, physical inactivity, unhealthful eating, inflammation, and hypercoagulation. The accumulation of adipose tissue (adiposity) and dysfunctional adipose tissue (adiposopathy) contribute to most, if not all, of the cardiometabolic risk factors. Adipose tissue promotes atherosclerosis through several different pathologic mechanisms, which are reviewed in this report. The treatment of obesity should focus on reducing fat mass and minimizing adipocyte dysfunction. Conclusion: Adipose tissue contributes to the development of insulin resistance, hyperglycemia, atherogenic dyslipidemia, and arterial hypertension and favors a prothrombotic and proinflammatory state. Adipose tissue dysfunction increases cardiometabolic risk through a variety of mechanisms. (Endocr Pract. 2010;16:692-698)
引用
收藏
页码:692 / 698
页数:7
相关论文
共 39 条
  • [1] Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach
    Bays, H
    Mandarino, L
    DeFronzo, RA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) : 463 - 478
  • [2] Is adiposopathy (sick fat) an endocrine disease?
    Bays, H. E.
    Gonzalez-Campoy, J. M.
    Henry, R. R.
    Bergman, D. A.
    Kitabchi, A. E.
    Schorr, A. B.
    Rodbard, H. W.
    Grp, Adiposopathy Working
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (10) : 1474 - 1483
  • [3] Adiposopathy: why do adiposity and obesity cause metabolic disease?
    Bays, Harold
    Ballantyne, Christie
    [J]. FUTURE LIPIDOLOGY, 2006, 1 (04): : 389 - 420
  • [4] Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia
    Bays, Harold
    Abate, Nicola
    Chandalia, Manisha
    [J]. FUTURE CARDIOLOGY, 2005, 1 (01) : 39 - 59
  • [5] Bays Harold E, 2008, Expert Rev Cardiovasc Ther, V6, P343, DOI 10.1586/14779072.6.3.343
  • [6] The endocannabinoid system in the regulation of cardiometabolic risk factors
    Bellocchio, Luigi
    Vicennati, Valentina
    Cervino, Cristina
    Pasquali, Renato
    Pagotto, Uberto
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (12A) : 7P - 17P
  • [7] Metabolic origins and clinical significance of LDL heterogeneity
    Berneis, KK
    Krauss, RM
    [J]. JOURNAL OF LIPID RESEARCH, 2002, 43 (09) : 1363 - 1379
  • [8] Adipose Tissue Dysfunction in Obesity
    Bluehre, M.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2009, 117 (06) : 241 - 250
  • [9] The pathobiology of diabetic complications - A unifying mechanism
    Brownlee, M
    [J]. DIABETES, 2005, 54 (06) : 1615 - 1625
  • [10] Lipoprotein management in patients with cardiometabolic risk
    Brunzell, John D.
    Davidson, Michael
    Furberg, Curt D.
    Goldberg, Ronald B.
    Howard, Barbara V.
    Stein, James H.
    Witztum, Joseph L.
    [J]. DIABETES CARE, 2008, 31 (04) : 811 - 822